Comparison of S‐1 plus oxaliplatin (SOX) and capecitabine plus oxaliplatin (XELOX) as adjuvant chemotherapies for stage II and III gastric cancer after D2 resection: A single‐center retrospective study

BACKGROUND: Capecitabine plus oxaliplatin (XELOX) as adjuvant therapy for gastric cancer (GC) reduces cancer recurrence and improves survival. S‐1 plus oxaliplatin (SOX) is well‐tolerated and effective against advanced GC, and also be used widely in adjuvant treatment. However, data comparing SOX an...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Asia Pac J Clin Oncol
Autors principals: Jiang, Zhichao, Sun, Yongkun, Zhang, Wen, Cui, Chengxu, Yang, Lin, Zhou, Aiping
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2020
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7318315/
https://ncbi.nlm.nih.gov/pubmed/32077628
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ajco.13321
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars